Horizon Kinetics Asset Management LLC Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Horizon Kinetics Asset Management LLC reduced its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,239 shares of the company’s stock after selling 443 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in CRISPR Therapeutics were worth $481,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cetera Investment Advisers grew its stake in CRISPR Therapeutics by 451.3% during the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock valued at $2,324,000 after acquiring an additional 27,915 shares in the last quarter. CWM LLC grew its position in shares of CRISPR Therapeutics by 11,871.1% during the second quarter. CWM LLC now owns 22,386 shares of the company’s stock valued at $1,209,000 after purchasing an additional 22,199 shares in the last quarter. Capital Advisors Inc. OK increased its holdings in shares of CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after purchasing an additional 22,583 shares during the last quarter. Granite Bay Wealth Management LLC purchased a new stake in shares of CRISPR Therapeutics in the second quarter worth about $2,375,000. Finally, International Assets Investment Management LLC bought a new position in CRISPR Therapeutics during the third quarter valued at approximately $1,825,000. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 1.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,382 shares of company stock worth $1,917,679 in the last 90 days. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Price Performance

CRSP stock opened at $50.40 on Tuesday. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10. The business has a 50-day moving average price of $47.98 and a 200 day moving average price of $51.73. The company has a market capitalization of $4.30 billion, a P/E ratio of -17.81 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the previous year, the firm posted ($1.41) earnings per share. On average, analysts anticipate that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CRSP. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, November 7th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Finally, Barclays dropped their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $74.94.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.